Allergy Therapeutics PLC (LON:AGY) Tim Higenbottam R&D Director on caught up with DirectorsTalk to discuss the G204 phase 2 study, selection criteria, its comparison to GMM and the phase 3 study.
The company provide information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with a special focus on allergy vaccination (also known as specific immunotherapy or desensitisation therapy). Allergy vaccination is a successful treatment that deals with the underlying cause of allergies and not just the symptoms! Allergy Therapeutics has a long-term commitment to the development of innovative therapies for allergy treatment and allergy prevention.
Allergy Therapeutics plc has always and will continue to put the needs of customers and, most importantly, the patients first. During our 80-year history, Allergy Therapeutics has laid the foundations of modern specific immunotherapy, leading the way using the latest research and development methods, and pioneering the use of allergoids and alternative adjuvants to improve the immunogenic effect and safety of specific immunotherapy. Therefore we are a fully integrated speciality pharmaceutical company with a profitable core business and patent protected development of ground breaking allergy vaccines. The company has the potential to transform allergy treatment with an established range of diagnostics and specific aluminium-free immunotherapy vaccines.